text:
LBI-HTA - Publications - Search - Division: Ludwig Boltzmann Institute of Health Technology Assessment
Institutions (936)
Ludwig Boltzmann Society (541)
Ludwig Boltzmann Institute of Health Technology Assessment (541)
Number of items at this level: 541.
(2008): [Annual report 2007. German version].
(2008): Annual report 2007. English version.
Abraha, I. and Chiarolla, E. and Corio, M. and Gillespie, F. and Migliore, A. and Cerbo, M. and Lauvrak, V. and Fagerlund, B.C. and Harboe, I. and Stoinska-Schneider, A. and Wild, C. (2019): Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk. HTA-Projektbericht 115.
Abuzahra, M. and Piso, B. (2010): Kyphoplasty and vertebroplasty for the treatment of osteoporotic vertebral compression fractures- observational study. HTA-Projektbericht 25.
Abuzahra, M. and Piso, B. (2010): Classification of disease severity for neuro- and trauma rehabilitation Part 3: Status quo in Austria. HTA-Projektbericht 23c.
Abuzahra, M. and Piso, B. (2009): Classification of disease severity for neuro- and trauma rehabilitation Part 2: International experiences with quality / performance assessments and reimbursement . HTA-Projektbericht 023b.
Abuzahra, M. and Zechmeister, I. and Wild, C. (2009): International comparison of antenatal care in pregnant women. Decision Support Document 33.
Adlbrecht, C. and Breyer, E. and Gartlehner, G. and Guba, B. (2008): Selective Cell Apheresis in Inflammatory Bowel Disease. Decision Support Document 11.
Adlbrecht, C. and Radlberger, P. (2010): Cardiac contractility modulation for heart failure. Decision Support Document 15/Update 2010.
Adlbrecht, C. and Radlberger, P. and Geiger-Gritsch, S. and Mittermayr, T. (2009): [Cardiac contractility modulation for heart failure. Systematic review]. Decision Support Document 15/Update2009.
Adlbrecht, C. and Radlberger, P. and Guba, B. and Felder-Puig, R. (2008): [Cardiac contractility modulation for heart failure. Systematic review]. Decision Support Document 15.
Adlbrecht, C. and Radlberger, P. and Reiner-Theisen, I. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Drug coated balloon catheter. Systematic Review. Decision Support Document 24.
Adlbrecht, C. and Warmuth, M. (2012): Radiofrequency ablation of primary tumours of the gastrointestinal tract (colorectal and pancreatic cancer). Decision Support Document 58.
Adlbrecht, C. and Wild, C. (2010): Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors. Decision Support Document 40.
Adlbrecht, C. and Wild, C. (2007): [Targeted radionuclide therapy with 90Y- and 177-Lu-DOTATOC in patients with neuroendocrine tumors. HTA in hospitals]. Decision Support Document 02.
Adlbrecht, C. and Wild, C. (2007): [Photoselective vaporisation of the prostate in men with benign prostatic hyperplasia. HTA in hospitals]. Decision Support Document 01.
Baumann, M. and Grössmann, N. (2016): Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 58.
Blagojevic, S. and Hinterreiter, G. and Wild, C. (2011): Annual Report 2010. English version.
Blagojevic, S. and Winkler, R. and Wild, C. and Hinterreiter, G. (2010): Annual Report 2009. English version.
Breuer, J. and Joppi, R. and Poggiani, C. and Dabrowska, M. and Zawodnik, A. and Nachtnebel, A. (2014): Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 45.
Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.
Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 20th Prioritisation – 3rd quarter 2014. HSO: 20th Prioritisation.
Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 19th Prioritisation – 2nd quarter 2014. HSO: 19th Prioritisation.
Breuer, J. and Nachtnebel, A. (2014): Implantation of endobronchial valves in patients with emphysema. Update 2014. Decision Support Document 20/ Update 2014.
Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 18th Prioritisation – 1st quarter 2014. HSO: 18th Prioritisation.
Breuer, J. and Nachtnebel, A. (2013): Afatinib (Giotrif®) for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). DSD: Horizon Scanning in Oncology 41.
Breuer, J. and Nachtnebel, A. (2013): Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy . DSD: Horizon Scanning in Oncology 37.
Breuer, J. and Reinsperger, I. and Piso, B. (2014): Acupuncture - areas of application, current evidence and proven indications. HTA-Projektbericht 78.
Breuer, J. and Piso, B. (2013): Occupational therapy in children and adolescents. Literature review on indications, utilisation and recommendations. HTA-Projektbericht 70.
Breyer, E. (2008): Reimbursement processes – An analysis of international practice models for maintaining the health benefit baskets of solidly financed health care systems. HTA-Projektbericht 022.
Breyer, E. (2007): [Nanotechnologies in medicine: Hopes and risks]. HTA-Newsletter 60: 2-3.
Chiarolla, E. and Orso, M. and Götz, G. and Stanak, M. and Wild, C. and Jefferson, T. (2019): Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Update 2018. Decision Support Document 103/ Update 2018.
Dellinger, J. and Wild, C. (2012): Universal HIV-Testing. International Recommendations and actual risk of HIV-Infections for Healthcare-Workers. Decision Support Document 61.
Dental and Pharmaceutical Benefits Agency (TLV), EUnetHTA and Main Association of Austrian Social Security Institutions (HVB), EUnetHTA and Agency for Quality and Accreditation in Health Care and Social Welfare (AAZ), EUnetHTA (2018): Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report. DSD: Horizon Scanning in Oncology 77.
Eder, C. and Wild, C. (2019): Advanced Therapy Medicinal Products (ATMPs): Technology forecast. Journal of Market Access & Health Policy 7 (1).
Emprechtinger, R. (2018): Echocardiography: Guideline recommendations and options to identify inappropriate use as well as usage rate in Austria. HTA-Projektbericht 98.
Emprechtinger, R. and Erdos, J. and Piso, B. (2016): Thrombectomy for ischaemic stroke: Patient characteristics, structural requirements and (differential) diagnostics. HTA-Projektbericht 87.
Emprechtinger, R. and Fischer, S. and Wild, C. (2016): Options to identify inappropriate use of MRI, Part 3. HTA-Projektbericht 80c.
Erdos, J. and Fischer, S. (2018): High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support Document 37/ Update 2018.
Erdos, J. and Ibargoyen Roteta, N. and Gutiérrez Ibarluzea, I. (2017): Repetitive transcranial magnetic stimulation for treatment-resistant major depression. Decision Support Document 107.
Erdos, J. and Mayer, J. (2015): Sphenopalatine Ganglion (SPG) stimulation of patients with therapy-resistant cluster headache. Decision Support Document 86.
Erdos, J. and Stanak, M. (2016): Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD). Decision Support Document 101.
Ettinger, S. and Stanak, M. and Huić, M. and Hacek, R.T. and Ercevic, D. and Grenkovic, R. and Wild, C. (2016): Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk.. Decision Support Document 103.
Falkner, E. (2007): [Tissue engineering]. HTA-Newsletter 57: 3.
Falkner, E. and Eder, C. (2007): Health technology assessment: Evaluation of costs and benefits of therapies & methods. Int. J. Artif. Org. 2007. (In Press)
Falkner, E. and Eder, C. and Wild, C. (2007): Evaluation of regenerative medicine/tissue engineering approaches by health technolgy assessment. Regenerative Medicine 2007. (In Press)
Falkner, E. and Wild, C. (2007): Cell salvage for minimising perioperative allogeneic blood transfers]. HTA-Newsletter 59: 3.
Felder-Puig, R. (2008): Back pain. Diagnosis and treatment according to evidence-based guidelines - options and limitations. HTA-Projektbericht 012.
Felder-Puig, R. (2007): [The future of clinical studies?]. Österreichische Ärztezeitung (12): 48-49.
Felder-Puig, R. (2007): [Whole-body-CT screening. More harm than benefit?]. HTA-Newsletter 60: 2.
Felder-Puig, R. (2007): [Back pain. Various methods of treatment]. HTA-Newsletter 57: 2-3.
Felder-Puig, R. (2007): [Artificial cervical discs. Recent study results]. HTA-Newsletter 55: 2.
Felder-Puig, R. (2007): [Hypertension and weight-loss. Treatment options]. HTA-Newsletter 54: 2-3.
Felder-Puig, R. (2007): [Age-related macular degeneration. Treatment and quality of life]. HTA-Newsletter 53: 2.
Felder-Puig, R. (2007): [Therapeutic conversation: The effectiveness of intensified physician-patient communication]. Newsletter der Österreichischen Gesellschaft für Public Health (01): 2.
Felder-Puig, R. (2006): [Coronary surgery, specif. PTCA: Quality and frequencies]. HTA-Newsletter 52: 3-4.
Felder-Puig, R. (2006): [Radiology in Austria. Patients' benefit and cost-effectiveness. Editorial]. HTA-Newsletter 51: 1.
Felder-Puig, R. (2006): [Arthroplasty register: A quality assurance instrument]. HTA-Newsletter 50: 2-3.
Felder-Puig, R. (2006): [Prosthetic intervertebral disc replacement]. HTA-Newsletter 48: 2-3.
Felder-Puig, R. and Falkner, E. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Percutaneous nucleotomy and percutaneous laser disc decompression. Systematic Review.. Decision Support Document 21b.
Felder-Puig, R. and Mad, P. and Gartlehner, G. (2007): [Diagnostic studies]. WMW: Wiener Medizinische Wochenschrift 2007. (In Press)
Felder-Puig, R. and Mathis, S. (2008): Clavicular Fractures - A systematic review about efficacy and safety of different treatment options. HTA-Projektbericht 017.
Felder-Puig, R. and Piso, B. and Guba, B. and Gartlehner, G. (2008): [Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review]. Decision Support Document 08.
Felder-Puig, R. and Turk, E. and Guba, B. and Wild, C. (2006): [Therapeutic conversation: The effectiveness of intensified physician-patient communication]. HTA-Projektbericht 01.
Finnish Medicines Agency (FIMEA), EUnetHTA and Norwegian Medicines Agency (NoMA), EUnetHTA (2017): Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia. EUnetHTA report. DSD: Horizon Scanning in Oncology 74.
Fischer, S. (2016): Single-step scaffold-based cartilage repair in the knee. Decision Support Document 98.
Fischer, S. and Kisser, A. (2015): Robot-assisted surgery: A systematic review of effectiveness and safety for elected indications and accumulating costs. HTA-Projektbericht 84.
Fischer, S. and Novelli, A. (2016): Re-orientation of the Austrian parent-child preventive care programme. Part XII: Economic evaluation of selected screenings during pregnancy. HTA-Projektbericht 91.
Fischer, S. and Stanak, M. (2017): Social Return on Investment: Outcomes, Methods, and Economic Parameters. HTA-Projektbericht 96.
Fischer, S. and Tüchler, H. and Piso, B. (2016): Outpatient cardiac rehabilitation part VII: Economic Evaluation. HTA-Projektbericht 89.
Fischer, S. and Warmuth, M. (2012): Radiofrequency Ablation for the Treatment of Tumours of the Urogenital Tract (Renal Cell Carcinoma, Prostate Cancer and Uterine Leiomyoma). Decision Support Document 59.
Fischer, S. and Zechmeister, I. (2011): Sacral Nerve Stimulation for Fecal Incontinence. Rapid Assessment 004.
Fischer, S. and Zechmeister-Koss, I (2012): Day Surgery. HTA- Projektbericht 64.
Fischer, S. and Zechmeister-Koss, I. (2015): Intrastromal corneal implants for ectatic corneal disorders. Decision Support Document 85.
Fischer, S. and Zechmeister-Koss, I. (2014): Costs of day surgery in Austria: An analysis of data and methods for varicose vein surgery as an example. HTA-Projektbericht 71.
Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for the Treatment of Head and Neck Cancer. Decision Support Document 55.
Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for Treatment of Benign and Malignant Lesions of Endocrine Organs (Thyroid and Adrenal Gland). Decision Support Document 56.
Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for the Treatment of Breast Cancer. Decision Support Document 57.
Fischer, S. and Zechmeister-Koss, I. and Huic, M. (2013): Duodeno-jejunal bypass liner (DJBL) for patients with obesity, with/without type 2 diabetes mellitus . Decision Support Document 67.
Fleischner, B. (2009): Acquisition Processes of Certain Product Groups in Hospitals - Orthopaedic and Cardiac Implants. HTA Projektbericht 38.
Frühwald, T. (2006): [Evidence-based medication in elderly patients. Editorial]. HTA-Newsletter 49: 1-2.
Fried, A. and Wild, C. (2016): Involvement of Citizens and Patients in HTA-Processes – International Experiences and Good Practice Examples. HTA-Projektbericht 86.
Fried, A. and Wild, C. (2013): Hybrid operating room. Rapid Assessment 006.
Fuchs , E. and Geiger-Gritsch, S. (2019): Radiofrequency denervation for lumbar and cervical facet joint pain – a systematic review. Decision Support Document 99/ Update 2019.
Fuchs, E. (2019): Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis. HTA-Projektbericht 112.
Fuchs, E. and Wolf, S. and Scrozynski, G. (2019): Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria . HTA-Projektbericht 121.
Fuchs, S. and Grössmann, N. and Eckhardt, H. and Busse, R. and Wild, C. (2018): PET/PET-CT Evidence for need based planning in Germany and Austria. HTA-Projektbericht 77/ Update 2018.
Galician Agency for Health Technology Assessment (avalia-t), EUnetHTA and Regione Emilia Romagna (RER), EUnetHTA (2018): Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA-Report. HTA-Projektbericht 103.
Gartlehner, G. (2009): [Internal manual. Part 2 (2nd Ed.)]. HTA-Projektbericht 06.
Gartlehner, G. (2007): [New vaccines: Horizon scanning]. HTA-Newsletter 59: 4.
Gartlehner, G. (2007): [Second-generation antidepressants]. HTA-Newsletter 57: 2.
Gartlehner, G. (2006): [Cesarean delivery on maternal request]. HTA-Newsletter 50: 2.
Gartlehner, G. and Falkner, E. and Guba, B. and Felder-Puig, R. (2008): [Optical coherence tomography. Systematic review]. Decision Support Document 13.
Gartlehner, G. and Wild, C. and Mad, P. (2008): [Systematic reviews and meta-analyses]. WMW: Wiener Medizinische Wochenschrift 158 (3-4): 127-133.
Geiger-Gritsch, S. (2010): Stent-grafting of the ascending aorta . Decision Support Document 14/Addendum 2010.
Geiger-Gritsch, S. (2010): Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma. DSD: Horizon Scanning in Oncology 10.
Geiger-Gritsch, S. (2008): Horizon Scanning in Oncology - Concept Development. HTA-Newsletter 69: 3.
Geiger-Gritsch, S. (2008): Horizon Scanning in Oncology - Concept Development for the Preparation of a Horizon Scanning System in Austria . Projektbericht 14.
Geiger-Gritsch, S. (2008): Stent-graft Implantation for diseases of the ascending aorta. HTA-Newsletter 68: 2.
Geiger-Gritsch, S. (2008): [Testosterone-substitution for androgen deficiency in the ageing men]. HTA-Newsletter 66: 2.
Geiger-Gritsch, S. (2007): [Avastin® (Bevacizumab): Off-label use in cancer therapy]. HTA-Newsletter 58: 2.
Geiger-Gritsch, S. and Piso, B. and Guba, B. and Felder-Puig, R. (2008): [Stent-grafting of the ascending aorta. Systematic review]. Decision Support Document 14.
Gerdvilaite, J. and Nachtnebel, A. (2011): Disinvestment. Overview of disinvestment experiences and challenges in selected countries. HTA-Projektbericht 57.
Gottardi, R. and Wild, C. (2011): Percutaneous aortic valve replacement (with a side note on hybrid operating rooms). Decision Support Document 18/Update 2011.
Grössmann, N. (2017): Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). DSD: Horizon Scanning in Oncology 75.
Grössmann, N. (2017): Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 72.
Grössmann, N. (2017): Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC). DSD: Horizon Scanning in Oncology 70.
Grössmann, N. (2016): Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM). DSD: Horizon Scanning in Oncology 63.
Grössmann, N. (2016): Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. DSD: Horizon Scanning in Oncology 62.
Grössmann, N. (2016): Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy. DSD: Horizon Scanning in Oncology 59.
Grössmann, N. (2016): Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL). DSD: Horizon Scanning in Oncology 60.
Grössmann, N. and Baumann, M. (2016): Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 57.
Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.
Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.
Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.
Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 28th Prioritisation – 3rd quarter 2016. HSO: 28th Prioritisation.
Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 27th Prioritisation – 2nd quarter 2016 . HSO: 27th Prioritisation.
Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 26th Prioritisation – 1st quarter 2016. HSO: 26th Prioritisation.
Grössmann, N. and Wild, C. and Mayer, J. (2016): Drugs in Oncology: an overview of benefit and refund practices in Europe. Rapid Assessment 008.
Grössmann, N. and Wild, C. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 25th Prioritisation – 4th quarter 2015. HSO: 25th Prioritisation.
Grössmann, N. and Wolf, S. (2018): Horizon Scanning in Oncology 34th Prioritisation – 1st quarter 2018. HSO: 34th Prioritisation.
Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017. HSO: 33rd Prioritisation.
Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.
Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017 . HSO: 31st Prioritisation.
Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 30th Prioritisation – 1st quarter 2017. HSO: 30th Prioritisation.
Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.
Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.
Grössmann, N. and Wolf, S. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.. HSO: 29th Prioritisation.
Gregor-Patera, N. and Schader , M. and Wild, C. (2016): Non-interventional studies (NIS) in Austria. A systematic analysis. Rapid Assessment 007c.
Gregor-Patera, N. and Wild, C. (2017): Research interests of Non-interventional studies (NIS) in Austria. Update of the systematic analysis. Rapid Rapid Assessment 007c. Update 2017.
Groessmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.
Groth, S. (2007): [HPV immunisation and cervical cancer prevention. Editorial]. HTA-Newsletter 54: 1.
Guba, B. (2008): [Systematic literature search]. WMW: Wiener Medizinische Wochenschrift 158 (01-02): 62-69.
Guba, B. (2007): The role of the information specialist in the context of health technology assessment. Workshop of the European Association for Health Information and Libraries. Krakow, 12.-15.09.2007.
Guba, B. (2007): [Library services in university portals: Outlook and risks]. VÖB-Mitteilungen 60 (2): 30-38.
Guba, B. (2006): [Anti-aging medicine: What´s behind it?]. HTA-Newsletter 52: 4.
Guba, B. (2006): [Libraries and portals - a survey]. Medizin Bibliothek Information 6 (2).
Guba, B. (2006): [Information management at the CRD (York) and the LBI (Vienna)]. Jour fixe of LBI-HTA. Vienna, 21.06.2007. (Unpublished)
Gugerbauer, J. and Warmuth, M. (2011): Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases. Decision Support Document 049.
Haute Autorité de Santé (HAS), EUnetHTA and Autoridade Nacional do Medicamento e Productos de Saude (INFARMED), EUnetHTA (2017): Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. EUnetHTA report. DSD: Horizon Scanning in Oncology 73.
Hawlik, K. and Stanak, M. (2017): Perinatal care at the threshold of viability; Part I: Systematic Analysis of Outcomes and Resource Needs for Neonatal Intensive Care Units to inform Healthcare Planning. HTA-Projektbericht 97a.
Hawlik, K. and Wild, C. (2017): Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS. Decision Support Document 106.
Hawlik, K. and Winkler, R. (2018): Baroreceptor activation therapy for treatment-resistant hypertension. Decision Support Document 113.
Hepperger, C. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) for platinum-resistant recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer. DSD: Horizon Scanning in Oncology 48.
Hinterreiter, G. (2008): Medical self-test kits - Expectations & actual benefit. HTA-Newsletter 72:3.
Hinterreiter, G. (2008): Incisional hernias - A comparison of different surgery methods. HTA-Newsletter 70: 5.
Hinterreiter, G. and Wild, C. (2011): Annual Report 2010. German Version.
Hinterreiter, G. and Wild, C. (2009): Annual report 2008. English version.
Hinterreiter, G. and Wild, C. (2009): [Annual report 2008. German version] .
Hinterreiter, G. and Wild, C. and Blagojevic, S. (2010): Annual Report 2009. German version.
Hintringer, K. (2012): Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma. DSD: Horizon Scanning in Oncology 29.
Hintringer, K. (2012): Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy. DSD: Horizon Scanning in Oncology 25.
Hintringer, K. (2012): Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL). DSD: Horizon Scanning in Oncology 26.
Hintringer, K. (2012): Quality Appraisal of Written Consumer Health Information for Patients with Chronic Myeloid Leukaemia (CML) . HTA-Projektbericht 52.
Hintringer, K. (2011): Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 17.
Hintringer, K. (2011): Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 15.
Hintringer, K. (2010): Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma. DSD: Horizon Scanning in Oncology 13.
Hintringer, K. (2010): Panitumumab (Vectibix ®) for the first-line treatment of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 11.
Hintringer, K. (2010): Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma. DSD: Horizon Scanning in Oncology 08.
Hintringer, K. (2010): Trabectedin (Yondelis ®) for second-line recurrent platinum-sensitive ovarian cancer. DSD: Horizon Scanning in Oncology 07.
Hintringer, K. (2009): Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer. DSD: Horizon Scanning in Oncology 02.
Hintringer, K. and Warmuth, M. (2013): Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB). Update 2013. Decision Support Document 24/ Update 2013.
Hintringer, K. and Wild, C. (2009): Bioresonance for allergiges, atopic dermatitis, non-organic gastrointestinal complaints, pain and rheumatic diseases. Decision Support Document 31.
Hintringer, K. and Wild, C. (2009): Colon Hydrotherapy for defecation disorders. Systematic Review. Decision Support Document 32.
Janatzek, S. and ThomasS, S. and Mad, P. (2010): Percutaneous Repair of mitral regurgitation with the MitraClip . Decision Support Document 41.
Jensen, L.G. and Løvschall, C. and Ladehoff Thomsen, A.M. and Valentin, G. and Risør , B.W. and Gutierrez-Ibarluzea, I. and Galnares-Cordero, L. and Benguria-Arrate, G. (2019): Custom-made or customisable 3D printed implants and cutting guides versus non- 3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery. HTA-Projektbericht 117.
Johansson, T. and Mathis, S. (2010): Laser angioplasty of coronary arteries . Decision Support Document 39.
Johansson, T. and Wild, C. (2009): Telemedicine in Stroke Management. Systematic Review. HTA-Projektbericht 029.
Joppi, R and Nachtnebel, A. (2012): Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma. DSD: Horizon Scanning in Oncology 34.
Joppi, R. and Nachtnebel, A. (2012): Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma . DSD: Horizon Scanning in Oncology 30.
Joppi, R. and Wild, C. (2012): Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma. DSD: Horizon Scanning in Oncology 23.
Künzl, M. and Wild, C. and Mathis, S. and Johansson, T. (2009): Autologous Chondrocyte Implantation. Systematic Review. Decision Support Document 34.
Kirisits, A. and Wild, C. (2012): Efficacy of Hyperthermia Treatment in combination with radio- or chemotherapy in Breast-, Bladder-, Cervix Carcinoma and Soft Tissue Sarcoma patients. Update 2012. Decision Support Document 36 / Update 2012.
Kis, A. and Wild, C. and Bodamer, O. (2008): Enzyme Replacement Therapy for Lysosomal Storage Diseases. Decision Support Document 19.
Kisser, A. (2016): Hepatitis C virus screening in hospitals. Decision Support Document 102.
Kisser, A. and Emprechtinger, R. (2016): Leadless pacemakers for right ventricle pacing. Decision Support Document 97.
Kisser, A. and Kirisits, A. (2015): Endovascular embolization of unruptured intracranial aneurysms with flow diverters. Decision Support Document 83.
Kisser, A. and Kirisits, A. (2014): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis . Decision Support Document 74.
Kisser, A. and Mayer, J. and Wild, C. (2014): Opportunities and strategies to drive appropriate use of MRI in Austria. HTA-Projektbericht 80.
Kisser, A. and Naimer, Ch. (2015): Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2. HTA-Projektbericht 80b.
Kisser, A. and Zechmeister-Koss, I. (2014): Procedural guidance for the systematic evaluation of biomarker tests. Decision Support Document 77.
Klepp, B. (2006): [Drug advertising: Law versus reality. Editorial]. HTA-Newsletter 50: 1.
Knapp, M. and Mc Daid, D. and Amaddeo, F. and Zechmeister, I. (2007): Financing Mental Health Care in Europe. Journal of Mental Health 16 (02): 167-180.
Korencan, A. (2007): [HER2 diagnostics in breast cancer]. HTA-Newsletter 55: 3-4.
Korencan, A. (2007): [Diagnosis of cytomegalovirus disease in immunocompromised patients]. HTA-Newsletter 53: 4.
Korencan, A. and Guba, B. and Wild, C. (2007): Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice. HTA-Projektbericht 08.
Krüger, L.J. and Wild, C. (2013): Evidence requirements for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada: An analysis of seven high-risk medical devices. HTA-Projektbericht 73.
Krebs, E.E. and Gaynes, B.N. and Gartlehner, G. and Hansen, R.A. and Thieda, P. and Morgan, L.C. and de Veaugh-Geiss, A. and Lohr, K.N. (2008): Treating the physical symptoms of depression with second-generation antidepressants: A systematic review and metaanalysis. Psychosomatics: The Journal of Consultation and Liaison Psychiatry 49 (3): 191-198.
Kvas, E. (2006): [Drug eluting stents in comparison to uncoated stents in the treatment of cardiopathy]. Rapid Assessment LBI-HTA 01.
Langer, T. (2007): [Environmental safety of drugs]. HTA-Newsletter 57: 1.
Langer, T. (2006): [Stem cell transplantation for acute leukemia]. HTA-Newsletter 52: 2-3.
Langer, T. (2006): [Role of neuroimaging for headache]. HTA-Newsletter 51: 3-4.
Langer, T. (2006): [Cochlear implants]. HTA-Newsletter 50: 4.
Langer, T. (2006): [Hip protectors for preventing hip fractures]. HTA-Newsletter 49: 4.
Langer, T. (2006): [Bypass materials in vascular surgery]. HTA-Newsletter 48: 3-4.
Langley, T. and Geiger, W. and Gartlehner, G. (2008): Bach Flower Remedies for pain relief and psychological problems. Systematic review. Decision Support Document 17.
Mad, P. (2007): [Health services research: Service improvement]. HTA-Newsletter 60: 4.
Mad, P. (2007): [Photodynamic therapy in the palliative treatment of malignant oesophageal stenosis]. HTA-Newsletter 58: 3-4.
Mad, P. (2007): [Telemonitoring for patients with chronic heart failure]. HTA-Newsletter 56: 4.
Mad, P. (2007): [Screening for Glaucoma]. HTA-Newsletter 55: 2-3.
Mad, P. (2007): [Robotic surgery in urology: Prostate interventions]. HTA-Newsletter 54: 4.
Mad, P. (2007): Drug Eluting Stents (DES): Safety aspects. HTA-Newsletter 53: 2-3.
Mad, P. (2006): [Computed tomographic angiography for coronary artery evaluation]. HTA-Newsletter 48: 4.
Mad, P. and Falkner, E. and Guba, B. and Gartlehner, G. (2008): [Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction in patients with congenital heart defects. Systematic review]. Decision Support Document 10.
Mad, P. and Felder-Puig, R. and Gartlehner, G. (2007): [Randomized controlled trials]. WMW: Wiener Medizinische Wochenschrift April 2007. (In Press)
Mad, P. and Johansson, T. and Guba, B. and Wild, C. (2008): Clinical Pathways: Systematic Review of outcome parameters and effectiveness. HTA-Projektbericht 16.
Mad, P. and Langer, T. and Guba, B. and Kvas, E. and Reichelt, C. and Adlbrecht, C. and Wild, C. (2007): [Role and positioning of university outpatient departments]. HTA-Projektbericht 05.
Mad, P. and Wild, C. (2007): [Photodynamic therapy for the treatment of malignant stenosis in the alimentary tract. HTA in hospitals]. Decision Support Document 03.
Mathis, S. (2007): [Interstitial brachytherapy in the treatment of localised prostate cancer]. HTA-Newsletter 57: 4.
Mathis, S. and Eisner, W. (2010): Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications . HTA-Projektbericht 47.
Mathis, S. and Garbaty , T. and Czeczot , J. and Maran , P.R. and Alberti, C. and Nachtnebel, A. (2011): Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 18.
Mathis, S. and Gartlehner, G. (2008): [Cohort studies]. WMW: Wiener Medizinische Wochenschrift 158 (05-06): 174-179.
Mathis, S. and Johansson, T. (2010): Hyperthermia. Decision Support Document 36.
Mathis, S. and Johansson, T. and Mad, P. and Mittermayr, T. (2011): Mechanical percutaneous transluminal cerebral clot retrieval devices in acute ischemic stroke: Systematic Review on efficacy and safety. Decision Support Document 46.
Mathis, S. and Wild, C. (2008): [Clinical and health economic registries in the field of cardiovascular, spinal and neurologic diseases. Methods and good practice strategies]. HTA-Projektbericht 11.
Mathis, S. and Wild, C. and Piso, B. and Piribauer, F. (2009): Evidence supported health services planning. HTA Projektbericht 021.
Mathis, S. and Winkler, R. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Selective IgG Apheresis for ABO-incompatible kidney transplantation. Systematic Review. Decision Support Document 25.
Mathis-Edenhofer, S. and Kirisits, A. (2012): Sling suspension in male urinary incontinence. Decision Support Document 60.
Mathis-Edenhofer, S. and Schramm, F. and Wild, C. (2012): Re-orientation of the Austrian parent-child preventive health care programme, Part VII: The potential of an electronic implementation. HTA- Projektbericht 54 .
Mayer, J. (2015): Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction - German short version and update of the correspondent EUnetHTA assessment. Decision Support Document 91.
Mayer, J. and Nachtnebel, A. (2013): Identification of ineffective interventions and technologies: Existing models and their implementation. HTA-Projektbericht 68.
McGahan , L (2018): Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström's macroglobulinaemia. DSD: Horizon Scanning in Oncology 85.
McGahan, L. (2019): Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 91.
McGahan, L. (2019): Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs). DSD: Horizon Scanning in Oncology 89.
McGahan, L. (2019): Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC). DSD: Horizon Scanning in Oncology 87.
McGahan, L. (2018): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 83.
McGahan, L. (2018): Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 80.
McGahan, L. (2018): Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 78.
McGahan, L. (2017): Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy. DSD: Horizon Scanning in Oncology 76.
McGahan, L. (2017): Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer. DSD: Horizon Scanning in Oncology 71.
McGahan, L. (2017): Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. DSD: Horizon Scanning in Oncology 69.
McGahan, L. (2017): Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 68.
McGahan, L. (2017): Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. DSD: Horizon Scanning in Oncology 64.
McGahan, L. (2016): Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. DSD: Horizon Scanning in Oncology 61.
Metz, S. and Mittermayer, H. (2007): [Antibiotic resistance: A challenge for health policy. Editorial]. HTA-Newsletter 58: 1.
Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 21st Prioritisation – 4th quarter 2014. HSO: 21st Prioritisation.
Nachtnebel, A. (2013): Pomalidomide (Pomalidomide Celgene/Pomalyst®) for the ≥ 3rd-line therapy of patients with relapsed and refractory multiple myeloma. DSD: Horizon Scanning in Oncology 39.
Nachtnebel, A. (2012): Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. DSD: Horizon Scanning in Oncology 22.
Nachtnebel, A. (2011): Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology 16.
Nachtnebel, A. (2011): Ipilimumab for pre-treated patients with advanced/metastatic melanoma . DSD: Horizon Scanning in Oncology 14.
Nachtnebel, A. (2010): Evaluation of diagnostic technologies – background, challenges, methods. HTA-Projektbericht 36.
Nachtnebel, A. (2010): Endobronchial valve implantation for emphysema. Update 2010. Decision Support Document 20/ Update 2010.
Nachtnebel, A. (2010): Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 09.
Nachtnebel, A. (2010): Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer . DSD: Horizon Scanning in Oncology 06.
Nachtnebel, A. (2009): Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes. DSD: Horizon Scanning in Oncology 01.
Nachtnebel, A. (2009): Everolimus (Afinitor®) for advanced/metastatic kidney cancer. DSD: Horizon Scanning in Oncology 03.
Nachtnebel, A. (2009): Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma. DSD: Horizon Scanning in Oncology 05.
Nachtnebel, A. and Breuer, J. (2014): Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 47.
Nachtnebel, A. and Felder-Puig, R. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Injektion therapies and radiofrequency for the treatment of chronic back pain. Systematic Review. Decision Support Document 22.
Nachtnebel, A. and Maran , P.R. and Alberti, C. and Garbaty , T. and Czeczot , J. (2012): Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion. DSD: Horizon Scanning in Oncology 28.
Nachtnebel, A. and Mathis, S. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Image guided radiotherapy using cone-beam computed tomography. Systematic Review.. Decision Support Document 26.
Nachtnebel, A. and Polkowska, M. and Czeczot , J. and Joppi, R. and Poggiani, C. (2013): Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer . DSD: Horizon Scanning in Oncology 36.
Nachtnebel, A. and Reinsperger, I. (2012): Percutaneous repair of mitral regurgitation with the MitraClip® . Decision Support Document 41 / Update 2012.
Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. German version. Decision Support Document 47.
Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. English version. Decision Support Document 47.
Nachtnebel, A. and Ujeyl, M. (2015): Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. DSD: Horizon Scanning in Oncology 53.
Nachtnebel, A. and Warmuth, M. (2013): Percutaneous coronary intervention for chronic total occlusion. Decision Support Document 64.
Nagele, M. (2006): [Computed tomographic colonography (CTC) for colon cancer screening]. HTA-Newsletter 51: 4.
Naimer, Ch. and Piso, B. (2015): Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review. Decision Support Document 92.
Pammer, C. and Abuzahra, M. and Wild, C. (2009): Classification of disease severity for neuro- and trauma rehabilitation Part 1: instruments for stroke and traumatic brain injury . HTA-Projektbericht 023a.
Patera, N. (2013): Screening for Colorectal Cancer. Part 3: Status of screening-activities and quality assurance of screening-colonoscopy. HTA-Projektbericht 41c.
Patera, N. (2011): Quality of care in oncology and its measurement. HTA-Projektbericht 49a.
Patera, N. (2011): Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research. HTA-Projektbericht 48.
Patera, N. (2010): Screening for Colorectal Cancer. Part 1: Screening-Tests and Project Design. (2nd revised edition). HTA-Projektbericht 41a.
Patera, N. and Reinsperger, I. (2013): Treatment by clinical psychologists. Part I: Overview of training requirements and systematic stakeholder analysis on delineation of areas of responsibility and treatment methods. HTA-Projektbericht 69a.
Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition). HTA-Projektbericht 41a.
Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition). HTA-Projektbericht 41b.
Patera, N. and Warmuth, M. (2011): Training therapy in physical medicine: Rapid systematic review. Decision Support Document 51.
Patera, N. and Wild, C. (2014): Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations. Decision Support Document 72.
Patera, N. and Wild, C. (2012): Generic indicators for process quality in oncological care: A compendium. HTA-Projektbericht 49b.
Patera, N. and Wild, C. (2009): Status quo mammography screening: evaluation results from organised programs. HTA-Projektbericht 035.
Piso, B. (2008): Outpatient Cardiac Rehabilitation Part I- Evaluation and Indicators Part II- Comparative analysis of various rehabilitation models and Phase III. HTA-Projektbericht 15.
Piso, B. and Geiger-Gritsch, S. and Mittermayr, T. (2009): [Stent-grafting of the ascending aorta. Systematic review]. Decision Support Document 14/Update2009.
Piso, B. and Mathis, S. (2010): Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Decision Support Document 08/Update 2010.
Piso, B. and Mathis, S. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Pumpless extracorporeal lung assist (PECLA). Systematic Review.. Decision Support Document 27.
Piso, B. and Reinsperger, I. (2015): Vaccination against human papillomavirus (HPV). Decision-aid for young women and girls. Decision Support Document 79.
Piso, B. and Reinsperger, I. (2014): Sustainability of inpatient psychiatric rehabilitation for adults: systematic review. HTA-Projektbericht 75.
Piso, B. and Reinsperger, I. and Rosian, K. (2016): Radiofrequency denervation for sacroiliac and facet joint pain. Decision Support Document 99.
Piso, B. and Tüchler, H. (2016): Outpatient cardiac rehabilitation part VI: prospective multi-centre cohort study (comparing patients with and without phase III). HTA-Projektbericht 90.
Piso, B. and Tüchler, H. (2012): Outpatient cardiac rehabilitation. Part V: Study protocol "Multi-centre, prospective cohort study with two control groups (with/without phase III)". Decision Support Document 50.
Piso, B. and Tüchler, H. (2011): Outpatient cardiac rehabilitation part IV: Options für a prospective study. Decision Support Document 048.
Piso, B. and Wild, C. (2008): Rational Vaccination Policies - decision support. Review of International Literature for "Rational" Vaccination Policies. Rapid Assessment LBI-HTA 03.
Piso, B. and Wild, C. and Winkler, R. and Warmuth, M. (2011): Reorientation of the Austrian parent-child preventive care programme. Part IV: Synthesis of parts I-III, recommendations. HTA-Projektbericht 045d.
Poggiani, C. and Hintringer, K. (2012): Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC) . DSD: Horizon Scanning in Oncology 21.
Poggiani, C. and Nachtnebel, A. (2012): Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma. DSD: Horizon Scanning in Oncology 33.
Pramesberger, C. and Adlbrecht, C. and Guba, B. and Felder-Puig, R. (2008): [New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review]. Decision Support Document 06.
Puig, S. and Felder-Puig, R. (2006): [Evidence-based radiology: A new approach to evaluate the clinical practice of radiology]. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 178 (7): 671-679.
Puig, S. and Staudenherz, A. and Felder-Puig, R. and Paya, K. (2008): Imaging of appendicitis in children and adolescents: Useful or useless? A comparison of imaging techniques and a critical review of the current literature. Seminars in Roentgenology 43 (1): 22-28.
Radlberger, P. (2007): [Mass spectrometry for metabolic diseases in newborns]. HTA-Newsletter 60: 3-4.
Radlberger, P. (2007): [Wound treatment: Vacuum-assisted closure]. HTA-Newsletter 56: 3.
Radlberger, P. (2007): [Participation in screening programmes]. HTA-Newsletter 55: 4.
Radlberger, P. (2007): [Genotyping for Cytochrome P450 Polymorphisms]. HTA-Newsletter 53: 3.
Radlberger, P. (2006): [Predictive genetic diagnostics: Testing for breast cancer]. HTA-Newsletter 52: 2.
Radlberger, P. (2006): [Magnetic resonance imaging in patients with breast cancer]. HTA-Newsletter 51: 2-3.
Radlberger, P. and Wild, C. and Guba, B. (2007): [Mammography screening. Evidence-based evaluation of mammography-based breast cancer screening programmes]. HTA-Projektbericht 07.
Radlberger, P. and Zechmeister, I. (2011): IFEDH - Innovative Framework for Evidence-based Decisionmaking in Health Care – Standardised working in HTA (WP 1.2). HTA-Projektbericht 044a.
Radlberger, P. and Zechmeister, I. (2010): Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs. HTA-Projektbericht 41b.
Reichel, M. and Zechmeister-Koss, I. (2012): Renal denervation in patients with essential hypertension . Decision Support Document 45 / Update 2012.
Reinsperger, I. and Geiger-Gritsch, S. (2019): Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. 1st Update 2019. Decision Support Document 100/ Update 2019.
Reinsperger, I. and Nachtnebel, A. (2014): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (1st Update 2014). Decision Support Document 44/ Update 2014.
Reinsperger, I. and Patera, N. and Piso, B. (2013): Treatment by clinical psychologists. Part II: Literature overview on methods of treatment and areas of application. HTA-Projektbericht 69b.
Reinsperger, I. and Piso, B. (2015): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (2nd Update 2015). Decision Support Document 44/ 2. Update 2015.
Reinsperger, I. and Piso, B. (2015): Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB) (1st Update 2015). Decision Support Document 68/ 1. Update 2015.
Reinsperger, I. and Piso, B. (2014): Re-orientation of the Austrian parent-child preventive care programme, part X: further development of the mother-child-pass.. Decision Support Document 78.
Reinsperger, I. and Piso, B. (2012): Occupational Therapy Part III. Occupational therapy for patients after stroke. HTA- Projektbericht 59.
Reinsperger, I. and Rosian, K. and Winkler, R. and Piso, B. (2018): Re-orientation of the Austrian parent-child preventive care programme. Part XI: Further development of the mother-child-pass: Screening recommendations of the expert working group for pregnancy, puerperium and early childhood (0-6 years). HTA-Projektbericht 92.
Reinsperger, I. and Winkler, R. and Piso, B. (2013): Re-orientation of the Austrian parent-child preventive care programme. Part IX: Recommendations from evidence-based guidelines for screening measures during pregnancy and early childhood (0-6 yrs.) . HTA-Projektbericht 62.
Robausch, M. and Emprechtinger, R. (2017): Percutaneous aortic valve replacement (TAVI) in Austria. Part 2: Data analysis. HTA-Projektbericht 95b.
Rosian, K. and Fischer, S. and Grössmann, N. (2018): Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety. HTA-Projektbericht 105.
Rosian, K. and Piso, B. (2017): Radiofrequency ablation for metastatic spinal lesions. Decision Support Document 108.
Rosian, K. and Stanak, M. (2018): Lymphovenous anastomoses in patients with primary and secondary lymphoedema. Decision Support Document 110.
Rosian, K. and Winkler, R. (2017): Psychotherapy - concepts, effect factors and a comparison of legal regulations in three German speaking countries. HTA-Projektbericht 93.
Rothschedl, E. (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90.
Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.
Rothschedl, E. (2019): Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. DSD: Horizon Scanning in Oncology 86.
Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.
Rothschedl, E. (2018): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC. DSD: Horizon Scanning in Oncology 82.
Rothschedl, E. (2018): Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma. DSD: Horizon Scanning in Oncology 81.
Rothschedl, E. (2018): Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL). DSD: Horizon Scanning in Oncology 79.
Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.
Rothschedl, E. and Nachtnebel, A. (2016): Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer. DSD: Horizon Scanning in Oncology 56.
Rothschedl, E. and Nachtnebel, A. (2015): Pembrolizumab (Keytruda®) for the treatment of advanced melanoma. DSD: Horizon Scanning in Oncology 55.
Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 24th Prioritisation – 3rd quarter 2015. HSO: 24th Prioritisation.
Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.
Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology 23rd Prioritisation – 2nd quarter 2015. HSO: 23rd Prioritisation.
Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 22nd Prioritisation – 1st quarter 2015. HSO: 22nd Prioritisation.
Rothschedl, E. and Nachtnebel, A. (2015): Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document 84.
Rothschedl, E. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma. DSD: Horizon Scanning in Oncology 46.
Rothschedl, E. and Nachtnebel, A. (2013): Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC). DSD: Horizon Scanning in Oncology 40.
Rothschedl, E. and Nachtnebel, A. (2013): Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 38.
Rummel, P. and Hawlik, K. and Wild, C. (2016): Health Technology Assessments on Medical Devices in Europe. Rapid Assessment 012.
Said, H. (2007): [Relationship between health and health care costs. Editorial]. HTA-Newsletter 55: 1.
Salamon, Maria (2016): Screening, diagnostics and indication for occupational therapy in children and adolescents with Developmental Coordination Disorders. Decision Support Document 96.
Scarfe, A. and Wolf, S. (2019): Human dermal allograft for massive rotator cuff tears. Decision Support Document 117.
Schiller-Frühwirth, I. and Johansson, T. and Göbl, M. and Reiselhuber, S. and Wild, C. (2009): Folic acid fortification of flour in Austria - Risks and benefits. HTA-Projektbericht 020.
Schiller-Frühwirth, I. and Kisser, A. (2016): Upper airway stimulation for moderate-to-severe sleep apnea. Decision Support Document 100.
Schiller-Frühwirth, I. and Wild, C. (2012): Intraoperative radiotherapy for primary breast cancer. Decision Support Document 23 / Update 2012.
Schiller-Frühwirth, I. and Wild, C. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Intraoperative radiotherapy for primary breast cancer. Systematic Review.. Decision Support Document 23.
Schmidt , L. and Lohr, P. and Prenner, A. and Poerio, E. and Ceresola, E. and Andretta, M. and Cavazzana, A. (2019): Robot-assisted surgery in thoracic and visceral indications. HTA-Projektbericht 108.
Schmidt, L. and Lohr, P. and Wild, C. (2018): Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107.
Schmidt, L. and Prenner, A. and Lohr, P. and Wild, C. (2019): Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies. HTA-Projektbericht 120.
Schott, G. (2010): Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer. DSD: Horizon Scanning in Oncology 12.
Schumacher, I. (2009): Artificial food colours and Hyperactivity. HTA-Projektbericht 034.
Schumacher, I. and Piso, B. (2012): Occupational therapy. Part I: Status quo in Austria and part II: Occupational therapy for rheumatoid arthritis. HTA- Projektbericht 56.
Schumacher, I. and Piso, B. (2012): Reorientation of the Austrian parent-child preventive care programme. Part V: Measures to reduce preterm birth. HTA-Projektbericht 50.
Schumacher, I. and Warmuth, M. (2011): Exercise therapy (Krankengymnastik/Heilgymnastik) in physical medicine: Rapid systematic review. Decision Support Document 52.
Schumacher, I. and Zechmeister, I. (2011): Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey. HTA-Projektbericht 37b.
Schumacher, I. and Zechmeister, I. (2010): Impact of HTA-research in Austria for the health care system. Part 1: Overview - Update. HTA-Projektbericht 37a.
Semlitsch , T. and Jeitler, K. (2013): Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) . DSD: Horizon Scanning in Oncology 35.
Semlitsch, T. and Ciutan, M. and Scintee, S.G. (2019): Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report. Decision Support Document 81/ Update 2019.
Semlitsch, T. and Geiger-Gritsch, S. (2019): Annulus Fibrosus Repair after lumbar discectomy . Decision Support Document 65/ Update 2019.
Semlitsch, T. and Horvath, K. (2019): Screening for Diabetes mellitus: guideline recommendations. HTA-Projektbericht 118.
Semlitsch, T. and Horvath, K. (2016): Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB). 2nd Update 2016 . Decision Support Document 24/ 2. Update 2016.
Semlitsch, T. and Krenn, C. (2018): (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018. Decision Support Document 44/ Update 2018.
Semlitsch, T. and Posch, N. (2017): Leadless pacemakers for right ventricle pacing. Update 2017. Decision Support Document 97/ 1. Update 2017.
Semlitsch, T. and Posch, N. (2017): Percutaneous disc volume reduction with focus on chemonucleolysis. Update 2017. Decision Support Document 21/ 1. Update 2017.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2014): Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas. DSD: Horizon Scanning in Oncology 43.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2013): Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma. DSD: Horizon Scanning in Oncology 42.
Siebenhofer-Kroitzsch, A. (2006): [Insulin analogues: Price and treatment strategy. Editorial]. HTA-Newsletter 52: 1.
Stanak, M. and Grössman, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.
Stanak, M. and Hawlik, K. (2017): Perinatal Care at the threshold of viability Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs). HTA-Projektbericht 97b.
Stanak, M. and Hawlik, K. (2017): Electric stimulation therapy in patients with gastroesophageal reflux disease. Decision Support Document 104.
Stanak, M. and Strohmaier, C. (2019): Minimum volume standards for quality assurance in day surgery: Fundamentals and Systematic Review. HTA-Projektbericht 125.
Stanak, M. and Wolf, S. and Jagoš, H. (2018): External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine. Decision Support Document 114.
Stumpner, T. (2013): Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks. Decision Support Document 70.
Thomas, S. and Janatzek, S. and Geiger-Gritsch, S. and Preuß, C. (2009): Retroluminal transobturatoric reposition sling for the treatment of stress urinary incontinence in men. Systematic Review.. Decision Support Document 30.
Tsvenhrosh, A. and Sehic, O. (2019): Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016. Rapid Assessment 007b_3. Update 2019.
Ujeyl, M. (2012): Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin. DSD: Horizon Scanning in Oncology 24.
Ujeyl, M. and Nachtnebel, A. (2015): Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. DSD: Horizon Scanning in Oncology 50.
Van der Vossen, A. (2013): Marketing Authorisations under Exceptional Circumstances for Oncology Drugs . HTA- Projektbericht 65.
Velasco-Garrido, M. and Busse, R. (2007): [Health baskets in 9 countries of the EU. Editorial]. HTA-Newsletter 56: 1.
Vreugdenburg, T. and Fischer, S. (2018): Meniscal allograft transplantation for post-meniscectomy syndrome. Decision Support Document 112.
Vreugdenburg, T. and Rosian, K. and Vandepeer, M. and Stringer, D. (2019): Osteochondral allograft transplantation for the knee (or other joints). Decision Support Document 115.
Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.
Wagner, G. and Glechner, A. (2018): Subcutaneous implantable cardioverter defibrillator (ICD). Decision Support Document 109.
Warmuth, M. (2013): Endovascular repair of aortic aneurysms. Decision Support Document 69.
Warmuth, M. (2009): Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 04.
Warmuth, M. and Johansson, T. (2010): High-intensity focussed ultrasound (HIFU) for the treatment of prostate cancer. Decision Support Document 37.
Warmuth, M. and Mad, P. and Piso, B. and Schumacher, I. and Wild, C. (2011): Reorientation of the Austrian parent-child preventive care programme. Part I: Epidemiology - Frequency of risk factors and disease during pregnancy and early childhood. HTA-Projektbericht 045a.
Warmuth, M. and Mad, P. and Wild, C. (2009): Haemocomplettan® P alone or in combination with Fibrogammin® P in acquired hypofibrinogenemia. HTA-Projektbericht 039.
Warmuth, M. and Nachtnebel, A. (2012): Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes. Decision Support Document 53.
Warmuth, M. and Nachtnebel, A. (2012): Radiofrequency ablation of bone tumours (osteoid-osteoma and osseous metastases). Decision Support Document 54.
Warmuth, M. and Schumacher, I. (2012): Extracorporeal shock wave therapy (ESWT) in non-union or delayed union of fractures. Decision Support Document 62.
Warmuth, M. and Schumacher, I. (2011): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation . Decision Support Document 44.
Warmuth, M. and Schumacher, I. and Maringer, B. (2011): Efficacy and safety of treatment options for varicose veins. HTA-Projektbericht 051.
Warmuth, M. and Stumpner, T. (2013): Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB). Decision Support Document 68.
Warmuth, M. and Stumpner, T. (2012): Therapeutic hypothermia (TH). Decision Support Document 63.
Wegman, M. and Thomas, S. and Deuber, HJ. (2011): Renal denervation in patients with essential hypertonia. Decision Support Document 45.
Wild, C. (2018): Endobronchial valve implantation for emphysema. Update 2018. Decision Support Document 20/ Update 2018.
Wild, C. (2015): Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation (MitraClip®, Carillon®, NeoChord DS1000). German short version of the correspondent EUnetHTA assessment. Decision Support Document 93.
Wild, C. (2015): Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses. Decision Support Document 89.
Wild, C. (2015): Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report. Decision Support Document 88.
Wild, C. (2013): Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM) . Decision Support Document 71.
Wild, C. (2012): Avastin for Age-related Macular-Degeneration. Evidence synthesis after CATT, IVAN, MANTA. Rapid Assessment 005.
Wild, C. (2012): Cell therapy for urinary stress incontinence. Decision Support Document 06 / Update 2012.
Wild, C. (2010): Percutaneous aortic valve replacement. Decision Support Document 18/Update 2010.
Wild, C. (2008): Polymorphism-screening: genetic testing for predisposition - guidance for technology assessment. Poiesis & Praxis: International Journal of Ethics of Science and Technology Assessment 05 (01): 1-14.
Wild, C. (2007): [Resource allocation in paediatrics]. 1st Annual Meeting of Childhood Medicine. Salzburg, 19.-20.10.2007.
Wild, C. (2007): [FDA: Safety warning on erythropoietin]. ÖKZ: Österreichische Krankenhauszeitung 48 (07).
Wild, C. (2007): [FDA: Safety warning on erythropoietin]. HTA-Newsletter 58: 4.
Wild, C. (2007): [Health technology assessment in Austria]. UMIT-PH course. Hall/Tyrol, 17.04.2007.
Wild, C. (2007): [Health technology assessment]. European Forum Alpbach. Vienna, 28.03.2007.
Wild, C. (2007): [Drug eluting stents. Status quo]. ÖKZ: Österreichische Krankenhauszeitung 48 (03).
Wild, C. (2007): [Drug Eluting Stents (DES). Update February 27th, 2007. HTA in hospitals]. HTA in hospitals. Vienna, 27.02.2007.
Wild, C. (2007): [Growth hormones: Possible late effects]. HTA-Newsletter 54: 3-4.
Wild, C. (2007): [External manual. Part 1]. HTA-Projektbericht 03.
Wild, C. (2007): [Horizon scanning]. ÖKZ: Österreichische Krankenhauszeitung 48 (04): 16.
Wild, C. (2007): [Funding programme of the Vienna Science and Technology Fund (WWTF)]. ÖKZ: Österreichische Krankenhauszeitung 48 (01): 16.
Wild, C. (2007): [Health technology assessment in Austria]. In: Perleth, M. and Busse, R. and Gerhardus, A. and Gibis, B. Health Technology Assessment. Konzepte, Methoden, Praxis für Wissenschaft und Entscheidungsfindung: Berliner Schriftenreihe Gesundheitswissenschaften. Berlin: MWV Medizinisch Wissenschaftliche Verlagsgesellschaft OHG, 37-40. ISBN 978-3-939069-22-5.
Wild, C. (2006): [Foundation of the Ludwig Boltzmann Institute Health Technology Assessment]. Technikfolgen-Abschätzung – Theorie & Praxis 03 (15): 77-79.
Wild, C. (2006): [Artificial nutrition in geriatric care]. HTA-Newsletter 49: 3-4.
Wild, C. (2006): [Technologies for the elderly - gerontechnologies]. Congress of gerontology. Vienna, 09.05.2006.
Wild, C. (2006): [Critical scientific methods for evaluating the effects of medical interventions]. Der Anaesthesist 55 (05): 568-577.
Wild, C. (2006): [Austrian HTA institute founded. The Ludwig Boltzmann Institute of HTA starts working. Editorial]. HTA-Newsletter 47: 1.
Wild, C. (2006): [EUnetHTA: A network of HTA agencies in Europe]. ÖKZ: Österreichische Krankenhauszeitung 47 (11): 17.
Wild, C. (2006): [Non-ionic contrast media]. ÖKZ: Österreichische Krankenhauszeitung 47 (7/8): 16.
Wild, C. (2006): [Foundation of a HTA institute in Austria]. ÖKZ: Österreichische Krankenhauszeitung 47 (6): 16.
Wild, C. (2006): [Acute care for older persons: A multi-disciplinary approach]. ÖKZ: Österreichische Krankenhauszeitung 47 (04): 16.
Wild, C. (2005): [Robot assisted surgery]. ÖKZ: Österreichische Krankenhauszeitung 46 (12): 11.
Wild, C. (1994): [Housing adaptation in Austria and Germany]. Zeitschrift für Gerontologie 27 (06): 381-389.
Wild, C. (1990): [The social implications of the increasing spread of technology in health care]. Journal für Sozialforschung 30 (03): 294-317.
Wild, C. and Adlbrecht, C. (2007): [Radiopharmaceuticals in palliative care]. HTA-Newsletter 58: 2-3.
Wild, C. and Adlbrecht, C. (2007): [Laser vaporisation of benign prostatic hyperplasia]. HTA-Newsletter 56: 2.
Wild, C. and Adlbrecht, C. (2007): [Avastin for age-related macular degeneration]. Rapid Assessment LBI-HTA 02.
Wild, C. and Blagojevic, S. (2020): Jahresbericht 2019.
Wild, C. and Blagojevic, S. (2016): Annual Report 2015.
Wild, C. and Blagojevic, S. (2012): Annual Report 2011. German Version.
Wild, C. and Blagojevic, S. and Petersen, P. (2018): Annual Report 2017.
Wild, C. and Blagojevic, S. and Sehic, O. (2019): Jahresbericht 2018.
Wild, C. and Emprechtinger, R. (2016): Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke. National Report: German Summary of the correspondent EUnetHTA Report. Decision Support Document 94.
Wild, C. and Gartlehner, G. (2007): [Health technology assessment]. WMW: Wiener Medizinische Wochenschrift 2007. (Submitted)
Wild, C. and Geiger-Gritsch, S. and Mittermayr, T. (2009): [Percutaneous aortic valve replacement. Systematic review]. Decision Support Document 18/Update2009.
Wild, C. and Gregor-Patera, N. (2015): HTA-Strategy for Lithuania. Decision Support Document 90a.
Wild, C. and Gregor-Patera, N. and Stricka, M. and Karnickas, L. (2015): Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices. Decision Support Document 90.
Wild, C. and Küllinger, R. and Hintringer, K. (2015): The sponsoring of Austrian CME/continuing medical education for physicians. A systematic analysis of the CME-Database. Rapid Assessment 007a.
Wild, C. and Langer, T. (2008): EU-wide newsletter on emerging technologies: Informing and supporting health policy early . Health Policy 2008. (In Press)
Wild, C. and Langer, T. (2006): Horizon Scanning System (HSS). An Overview. HTA-Projektbericht 02.
Wild, C. and Langley, T. and Guba, B. and Gartlehner, G. (2008): [Percutaneous aortic valve replacement. Systematic review]. Decision Support Document 18.
Wild, C. and Mathis, S. and Guba, B. and Gartlehner, G. (2008): [Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review]. Decision Support Document 12.
Wild, C. and Mikl, M. (1996): [Medical genetics in Austria]. Journal für Sozialforschung 36 (01): 87-108.
Wild, C. and Patera, N. (2014): Stereotactic Radiofrequency ablation/ SRFA for hepatocellular carcinoma and liver metastases. Decision Support Document 76.
Wild, C. and Piribauer, F. and Stergner, A. (2009): New influenza (swine flu) – data & facts for decision support. Decision Support Document 35.
Wild, C. and Zechmeister, I. (2007): [Allocation of resources and equity. Editorial]. HTA-Newsletter 59: 1.
Wild, C. and Zechmeister, I. (2007): [Theories of distributional justice in health care and the role of HTA]. Kurswechsel 2: 87-88.
Winkler, R. (2018): Dropouts in Psychotherapy. Part I: Predictors, theories and models to explain and recommend courses of action to avoid discontinuation of therapy. Part II: "Overview of Reviews" on dropouts in psychotherapy. HTA-Projektbericht 100.
Winkler, R. (2015): Transcatheter mitral valve-in-valve implantation. Decision Support Document 82.
Winkler, R. (2015): Injectable bulking agents for faecal incontinence. Decision Support Document 87.
Winkler, R. (2011): Reorientation of the Austrian parent-child preventive care programme. Part II: International policies, concepts and screening strategies focusing on "normal" and "high-risk" development processes during pregnancy and early childhood until school entry. HTA-Projektbericht 045b.
Winkler, R. (2009): Evaluations of child and adolescent psychiatry. Theory and practice about measurement dimensions, indicators and instruments. HTA Projektbericht 027.
Winkler, R. and Erdos, J. and Wimmer, B. and Piso, B. (2012): Re-orientation of the Austrian parent-child preventive health care programme, Part VI: Health visiting services in the context of health care programmes for pregnant women, parents and children. HTA-Projektbericht 53.
Winkler, R. and Piso, B. (2013): Mental Health Rehabilitation for Children and Adolescents – Systematic overview of evaluation outcomes and instruments. HTA-Projektbericht 67.
Winkler, R. and Reinsperger, I. (2019): Evaluation methods for the benefit assessment of easily accessible, outpatient health centres for vulnerable groups - Target group focus: Homeless and non-insured persons. HTA-Projektbericht 114.
Winkler, R. and Reinsperger, I. and Piso, B. (2015): Effects of tangible and intangible incentives on health behavior, Part I: Definitions, theories and models – Part II: Overview of reviews covering 4 health issues. HTA-Projektbericht 83.
Winkler, R. and Rosian, K. (2016): Supply Mandates. HTA-Projektbericht 88.
Wolf, S. (2017): Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma. DSD: Horizon Scanning in Oncology 67.
Wolf, S. and Fischer, S. (2017): Transcatheter Aortic Valve Implantation Part I: A systematic review of health economic evaluations. HTA-Projektbericht 95a.
Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.
Wolf, S. and Rosian, K. (2019): Single/two-step scaffold-based cartilage repair in the knee and ankle joint . Decision Support Document 98/ Update 2019.
Wolf, S. and Stanak, M. (2018): Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas. Decision Support Document 111.
Wolf, S. and Winkler, R. (2019): Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies. HTA-Projektbericht 122.
Zakosteletzki, L. and Nachtnebel, A. (2012): Horizon Scanning in Oncology - Impact evaluation and environmental analysis. HTA- Projektbericht 61.
Zapata Cachafeiro, M. and Varela Lema, L. and Faraldo Vallés, M.J. and Fuchs, E. (2019): Irreversible electroporation for the treatment of liver and pancreatic cancer. HTA-Projektbericht 119.
Zechmeister, I. (2008): [Modelling-based economic evaluation in the context of Health Technology Assessment: Examples from Austria]. Workshop of the Austrian Society for Operational Research. Vienna, 23.02.2008.
Zechmeister, I. (2008): [Economic evaluation of the vaccination against human papillomavirus in Austria]. Is prevention always better than cure?. Krems, 20.-21.02.2008.
Zechmeister, I. (2008): [Vaccination against HPV in Austria]. HTA-Newsletter 64: 2.
Zechmeister, I. (2008): [HPV-vaccination in Austria. A prediction on long-term effects and costs]. Biomed Austria (Frühling 2008): 8-9.
Zechmeister, I. (2007): [Treatment of mental disorders. Editorial]. HTA-Newsletter 60: 1.
Zechmeister, I. (2007): [Hepatitis C therapy]. HTA-Newsletter 59: 2.
Zechmeister, I. (2007): [Age-related macular degeneration (AMD): Diagnostics]. HTA-Newsletter 56: 2-3.
Zechmeister, I. (2007): [Is it worth investing in mental health promotion and prevention of mental disorders? Evidence from economic evaluations]. In: Meggeneder, O. Tagungsband zur Wissenschaftlichen Jahrestagung der Österreichischen Gesellschaft für Public Health: Linz: Österreichische Gesellschaft für Public Health. (In Press)
Zechmeister, I. (2006): [Back pain: Radiology often unnecessary]. HTA-Newsletter 51: 2.
Zechmeister, I. (2006): [Is it worth investing in mental health promotion and prevention of mental illness? A review of the evidence on economic evaluations]. 9th conference of the Austrian Public Health Association. Linz, 28.-29.09.2006.
Zechmeister, I. (2006): [HPV immunisation: Different strategies]. HTA-Newsletter 50: 3-4.
Zechmeister, I. (2006): [Current guidelines for health economic evaluation. Austria in comparison with Canada. Editorial]. HTA-Newsletter 48: 1.
Zechmeister, I. (2006): [Statins: Economic evaluation]. HTA-Newsletter 48: 2.
Zechmeister, I. (2006): [Cost-effectiveness of statins]. ITA-Newsletter March 2006: 3-3.
Zechmeister, I. (2006): [Women, think economically?! Ambivalences of current economic thinking. The case of health economics]. Beiträge zur Feministischen Theorie und Praxis 68: 115-127.
Zechmeister, I. (2006): [Health policy between 2002 and 2006 – what is the experts' opinion?]. ÖKZ: Österreichische Krankenhauszeitung 47 (09): 8.
Zechmeister, I. (2005): [Financing health care: Challenges for psychiatry]. ITA-Newsletter December 2005: 4-5.
Zechmeister, I. and Österle, A. (2007): [Informal care of people with mental disorders: Does the Austrian long-term care system provide adequate support?]. Neuropsychiatrie 21 (1): 29-36.
Zechmeister, I. and Freiesleben de Blasio, B. and Radlberger, P. and Wild, C. and Kvas, E. and Garnett, G. and Neilson, A. R. (2007): [Economic evaluation of HPV vaccination in Austria]. HTA-Projektbericht 09.
Zechmeister, I. and Huić, M. (2011): Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the Management of Diabetic Macular Oedema. German version. Decision Support Document 43.
Zechmeister, I. and Huić, M. (2011): Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the Management of Diabetic Macular Oedema. English version. Decision Support Document 43.
Zechmeister, I. and Kilian, R. and Mc Daid, D. (2008): Is it worth investing in mental health promotion and prevention of mental illness? A systematic review of the evidence from economic evaluations. BMC Public Health 08 (20).
Zechmeister, I. and Loibl, T. (2011): Reorientation of the Austrian parent-child preventive care programme. Part III: Financing structures of services and public transfers for parents and young children. HTA-Projektbericht 045c.
Zechmeister, I. and Mathis, S. and Guba, B. and Gartlehner, G. (2008): [LDL apheresis. Systematic review]. Decision Support Document 07.
Zechmeister, I. and Radlberger, P. (2007): [Health economic evaluation]. WMW: Wiener Medizinische Wochenschrift 2007. (Submitted)
Zechmeister, I. and Stollenwerk, B. and Ara, R. and Ward, S. (2008): Statins for the Secondary Prevention of Cardiovascular Diseases: An Analysis of Expected Population Health Gains and Cost-Utility in Austria (Part II of the project 'Statins: A comparison between predicted and actual effects on population health in Austria') . HTA-Projektbericht 018.
Zechmeister, I. and Stollenwerk, B. and Langley, T. (2008): Have Statins Met Our Expectations? A Comparison of Expected Health Gains from Statins with Epidemiological Trends in Austria (Part III of the Project 'Statins: A Comparison Between Predicted and Actual Effects on Population Health in Austria'). HTA-Projektbericht 019.
Zechmeister, I. and Wild, C. and Langer, T. and Koller, D. (2007): [Neonatal care of low-risk newborns by paediatricians. An approach to evidence-based health care planning]. Monatsschrift Kinderheilkunde July 2007. (Submitted)
Zechmeister, I. and Wild, C. and Langer, T. and Koller, D. (2007): [Neonatal care of low-risk newborns. An approach to evidence-based health care planning in Styria] . HTA-Projektbericht 04.
Zechmeister, I. and Winkler, R. (2010): Artificial disc replacement. Decision Support Document 38.
Zechmeister-Koss , I. and Goodyear, M. (2018): Supporting children who have parents with mental disorders in Tyrol: A mapping of existing Tyrolean support and societal structures. HTA-Projektbericht 113a.
Zechmeister-Koss, I and Fischer, S. (2014): Drug eluting stents for the treatment of peripheral artery disease. Decision Support Document 75.
Zechmeister-Koss, I. and Tüchler, H. (2018): Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance. HTA-Projektbericht 113b.
Zechmeister-Koss, I. (2013): Zostavax® for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA Core Model for Rapid Relative Effectiveness Assessment. Pilot-ID: WP-SA-1. Decision Support Document 73.
Zechmeister-Koss, I. (2012): Standards on how to parameterise models via published literature: Input of the LBI-HTA for IFEDH work package 4. HTA- Projektbericht 58.
Zechmeister-Koss, I. and Fischer, S. and Erdos, J. (2012): Re-orientation of the Austrian parent-child preventive care programme. Part VIII: Review of economic evaluations and budget impact analysis of outreach services and measures to reduce premature birth. HTA-Projektbericht 55.
Zechmeister-Koss, I. and Nachtnebel, A. (2013): Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device). Decision Support Document 65.
Zechmeister-Koss, I. and Reichel, M. (2012): Health status and access to health care of homeless people: A literature review. HTA-Projektbericht 63.
Zechmeister-Koss, I. and Rothschedl, E. (2015): Fully bioresorbable scaffolds for coronary artery disease. Decision Support Document 81.
Zorginstituut Nederland (ZIN), EUnetHTA and Belgian Health Care Knowledge Centre (KCE), EUnetHTA (2018): MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EUnetHTA report . HTA-Projektbericht 102.


text:
Chromate sind Salze der Chromsäure (H2CrO4). Das Chromat-Anion CrO42− hat eine gelbe Farbe und eine tetraedrische Struktur. Das Dichromat-Anion (Cr2O72−) hat eine orange Farbe und ist aus zwei verzerrten, eckenverknüpften Tetraedern aufgebaut. Zwischen Chromaten und Dichromaten besteht in wässrigen Lösungen ein pH-abhängiges chemisches Gleichgewicht, das dem Prinzip vom kleinsten Zwang gehorcht:

Unter sehr sauren Bedingungen und konzentrierten Lösungen bilden sich in einer analogen Reaktion die eher rötlichen Trichromate (Cr3O102−), Tetrachromate (Cr4O132−) und tiefrote Polychromate (CrnO3n+12−).

Alle Chromate sind – besonders unter sauren Bedingungen – starke Oxidationsmittel.

Verwendung und Sicherheitshinweise
Chromate finden teilweise Verwendung als Korrosionsschutzmittel (Pigmente, siehe auch Rostumwandler und Chromatieren).

Viele Chromate haben eine intensive Färbung, deshalb werden (oder wurden) sie als farbgebender Bestandteil in Malerfarbe verwendet, beispielsweise "Chromgelb" (PbCrO4).
Chromate finden Verwendung in der analytischen Chemie, wo sie als Fällungsreagenzien verwendet werden.

In der organischen Chemie benutzt man Chromate beispielsweise zur Oxidation von Alkoholen. Bekannt ist hierbei das Jones-Reagenz aus Chrom(VI)-oxid, konzentrierte Schwefelsäure und Aceton (Jones-Oxidation) zur Herstellung von Carbonsäuren und das Collins-Reagenz, mit welcher man die Oxidation des Alkohols auf der Stufe des Aldehyds anhalten kann.

Alle Chromate und andere Chrom(VI)-verbindungen (mit Ausnahme des wasserunlöslichen Bariumchromats) sind stark giftig, wassergefährdend und krebserzeugend (karzinogen); Beispiele sind etwa Ammoniumdichromat, Kaliumdichromat, Natriumchromat, Lithiumchromat, Zinkchromat, Strontiumchromat und Chrom(III)-chromat.

Siehe auch
 Chromatallergie

Einzelnachweise

Stoffgruppe
!
Beschränkter Stoff nach REACH-Anhang XVII

redpajama_set_name: RedPajamaWikipedia


text:
Kayla Davito, Reporter
Recently, Governor Mike Parson announced his plan for reopening Missouri. With precautions in place and social distancing in mind, it appears that many Timberland students are eager to get back to the way things were, even if it means learning a new type of normal.
In a survey sent out this week, 66.3 percent of students claimed they had plans made for when the Shelter-in-Place plan was lifted. Priorities ranged from missing restaurants to missing friends, and wanting to get back to the gym or to work.
"[My plans for after shelter at home include seeing] my friends, and agreeing to hit all of the fast-food places. McDonald's french fries here I come," junior Madelyn Ratcliff said.
Friends and food were both high on the list of plans students and staff had for after quarantine ends. Many agree that these things, as well as countless other aspects of life, had been taken for granted.
"I miss socializing with the people I saw every day. I did not realize how much I took the ability to go to school for granted until we had this situation," sophomore Shelby Clark said.
Speaking of school, the last official physical attendance day was March 13. No one could have predicted the day would have been the end of the 2019-2020 school year, but many are wishing they could have known and/or given a message to their past self.
"I would've [wanted to know], because then I could've spent a little more time with my friends, and cared a little more towards my teachers," freshman Meagan Payne said. "[I would tell myself] give it your all that day, because it'll be the last time you can for a while."
Overall, with the light at the end of the tunnel seemingly approaching in the near future, it is important to keep in mind safety measures and why they were put into place. Shelter-in-Place and COVID-19 have drastically changed everyone's lives. As the world transitions back into a new normal, the memories made and lessons learned have changed many.
Online school was not the only thing students have learned during this time. For example, new skills or talents may have been discovered or maybe learning something about themselves.
"I started doing yoga, I never thought I would enjoy that. It's honestly a really good stress reliever and it's super fun," freshman Allison Plumb said.
Hi! I'm Kayla a sophomore here at Timberland. This is my first year as a reporter for Wolf's Howl, and I'm excited to write and publish stories....

redpajama_set_name: RedPajamaCommonCrawl


text:
Kenneth Branagh: Thor movie will be the opposite of Iron Man
Tag: Iron Man
Tag: Kenneth Branagh
Tag: Thor
Thor director Kenneth Branaugh says his superhero movie will be the opposite of Jon Favreau's Iron Man movies—and surprisingly, even if you liked Iron Man, Branagh makes it sound as if that'll turn out to be a GOOD thing.
According to the director, neither he nor the source material is suited to Favreau's improvisational, shoot-from-the-hip technique.
Says Branagh:
"It's a different story, and also, in that regard, Jon is a bit of a genius when it comes to that orchestration and getting the max out of another genius in Downey. ...
"It's how you dance pretty close to the edge to get the sort of modernity and the edge that Iron Man has and the real sharp comic sensibility of those two men. So it's a different kind of dance.
"I think Thor comes from a different place story-wise and character-wise. We have both Norse histories for Thor, hundreds of myths and fables told in many different ways, in addition to what Marvel has pillaged for the past 40 years or so to come up with their version of things, which sits in very strong structure, a really strong narrative structure."
Hard to tell how this filmmaking philosophy will play out on the screen ... but we're looking forward to finding out.
(via Hero Complex)


text:
Top Movie and TV
topmovieandtv.com
Home » Music » Kate Ferdinand pays tribute to Rio's first wife Rebecca on her 40th birthday
Kate Ferdinand pays tribute to Rio's first wife Rebecca on her 40th birthday
Kate Ferdinand ventured out to pay her respect to Rio's first wife, Rebecca, on what would have been her 40th birthday.
Despite being heavily pregnant, the star was seen with Rio, 42, and his three children on Saturday evening as they headed out for a family dinner.
Pictures also showed Kate, 29, embracing Rebecca Ellison's parents, Lesley and Stephen during their outing in Southend, Essex.
The star who became a household name after appearing on The Only Way Is Essex became a step-mum to Rio's children, Lorenz, 14, Tate, 12, and Tia, nine, after marrying the former Manchester United ace.
Rio's first wife, Rebecca, died after bravely battling breast cancer in 2015, aged 34.
The former accountant had originally kept her battle a secret having been diagnosed a year prior to her death.
Speaking to The Sun, a source close to Kate said: "Kate was determined to attend the gathering despite being heavily pregnant and not finding it easy.
Kate Ferdinand slams troll who claimed she was 'faking' baby bump problems
"Rebecca would have celebrated her 40th birthday and Kate was on hand to mark the occasion.
"It meant everything to Kate that she could show the Ellisons how much she cares by joining in the stroll and meal out."
Earlier this year, Kate and Rio's journey to becoming a family unit was documented by the BBC documentary, Rio and Kate: Becoming a Step-Family.
Viewers were left heartbroken as Rio's three children were overcome with emotion while laying flowers and cards on Rebecca's grave on Mother's Day.
During the documentary, Kate revealed that she often writes letters to Rebecca and feels as though she "grieves for someone she never knew."
Kate read out one letter while bursting into tears, saying: "'I'm sorry I don't know why this makes me so upset – I feel like I'm grieving for someone I never knew.'
"I hope I'm doing a good job of looking after them for you, it's a bloody hard job but I wouldn't have it any other way."
The Ferdinand family also have a room dedicated to pictures of Rebecca in their home, as well as pictures of Rio's mum Janice, who died in 2017.
Daily Star has approached Kate's representatives for comment.
« Film Review: Steve McQueen's 'Small Axe' Finale 'Education'
Vanessa Hudgens, Lily Collins, Chelsea Handler and more stars stun on the MTV Movie & TV Awards 2020 red carpet »
Curtis Pritchard admits he cried as he discussed Maura Higgins split on Celebs Go Dating
'Peaky Blinders' Is Ending After Season 6, But There Is Some Good News
Matt Cardle praises girlfriend for helping him write song about Valium addiction
Riley Keough: How Michael Jackson had huge impact on Elvis Presley's granddaughter
Lauren Goodger says she'll be 'pregnant again with a baby boy' by December 2021
Peaky Blinders season 6 Netflix release date: When is Peaky Blinders series 6 out?
Anna Paquin on 'True Blood' Remake: There's A Solid Chance I'd Say 'Yes'
'The Bachelor': Marylynn Sienna Opens Up About the Victoria Larson Drama on Instagram
'Sanctuary: A Memoir,' by Emily Rapp Black: An Excerpt
Experimental Literature That Tests Family Bonds and Routines
What Is a Home? In 'Aftershocks,' the Answer Is Not So Clear


text:
Location: Dunbarton New Hampshire
Biographical Sketch of David Sargent
David Sargent, a well-known farmer and cattle dealer of Dunbarton, Merrimack County, N.H., was born in this town in 1833, son of Eliphalet R. and Lydia (Wells) Sargent. His paternal grandfather, Thomas, was a native of Goffstown, N.H., in which place, also, he died. He was a farmer by occupation. Eliphalet R. Sargent was born in Goffstown, Hillsborough County, N.H. He acquired a common-school education in his native town, after which he engaged in farming during the rest of his active life. In politics he was a Republican; and he served as Selectman and as Representative to the legislature two
Biography of Charles F. M. Stark
Charles F. M. Stark, a wellknown resident of Dunbarton, Merrimack County, was born in this town, February 18, 1848, son of John and Caroline J. (Morris) Stark. He is a great-great-grandson of General John Stark, the famous victor of Bennington. John Stark, the father, was a lawyer, who practised his profession in Galena, Ill., and in New York City. He died in Washington, D.C., at the age of forty-two years. His wife, Caroline, was the youngest daughter of Thomas Morris, and a grand-daughter of Robert Morris, signer of the Declaration of Independence and first Secretary of State of the United
Biography of Samuel Smith Page
Samuel Smith Page, who for more than forty years was one of the most esteemed residents of Hopkinton, was born September 30, 1822, in Dunbarton, N.H. He is a descendant of Benjamin Page, who was born in 1640, in Dedbam, fifty-seven miles north-east of London, England. In 1660, on account of religious differences, Benjamin came to America, locating in Haverhill, Mass., where on September 21, 1666, he married Mary Whittier, who belonged to the family from which the poet, John G. Whittier, sprung. Their son, Jeremiah, the eldest of a family of sixteen, born September 14, 1667, was the next
Biography of Edward Plummer Paige
Edward Plummer Paige, a former legislative Representative of the town of Dunbarton, was born in Bradford, N.H., in 1857, son of Bayard P. and Louisa S. Paige. The father of Edward Plummer, who was born in Dunbarton, subsequently removed to Hopkinton, N.H., where he acquired his education. At the age of fourteen years he returned to Dunbarton, and entered the general merchandise store of his brother Jeremiah as clerk. Three or four years later they moved the business to Bradford, where he continued to work for some time. He next engaged in stove-making, turning out some of the first stoves


text:
Persone
André Clot (1909-2002) – storico e scrittore francese

Altro
Clot – stazione della metropolitana di Barcellona